← Every company
Novo Nordisk A/S Patents
What Novo Nordisk A/S has filed at the patent office — applications as well as grants, because a filing is on the record eighteen months before anyone has to say what it was for.
NVO on carbonthat →Filings on file
51
Granted
4
Still pending
47
Filed under
6 names
51 filings
Newest filing first. A pending application has no patent number yet, and most never get one.
| Invention | Patent |
|---|---|
| TABLET FORMULATION COMPRISING A GLP-1 PEPTIDE AND A DELIVERY AGENTA61K 9/2013, A61K 38/26, A61P 3/04, A61P 3/10, A61K 9/1617, A61K 9/2004, A61K 9/2072, A61K 9/2077, A61K 9/2095Filed as Novo Nordisk A/S2026-05-29Simon Bjerregaard | pending |
| ALK7 COMBINATION TREATMENTSA61P 3/04, A61K 39/3955, A61P 3/10, A61K 38/17, A61K 38/22, A61K 38/26, A61K 45/00, A61K 45/06, A61K2039/505, A61K2039/507, C07K 14/605, C07K 16/2863, C07K 16/2869, C07K2317/76, A61K2300/00Filed as Novo Nordisk A/S2026-03-27Johan Fredrik Paulsson | pending |
| Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acidA61K 9/1617, A61K 9/2077, A61K 38/26, A61P 3/04, A61P 3/10, A61K 9/0053, A61K 9/2013, A61K 47/10, A61K 47/14, A61K 47/183, A61K 47/22Filed as Novo Nordisk A/S2026-03-27Simon Bjerregaard | pending |
| SOLID COMPOSITIONS COMPRISING A GLP-1 AGONIST AND A SALT OF N-(8-(2-HYDROXYBENZOYL)AMINO)CAPRYLIC ACIDA61K 9/20, A61K 38/26, A61P 25/28, A61P 43/00, A61P 3/00, A61P 9/00, A61P 3/04, A61P 3/06, A61P 3/10, A61P 15/08, A61P 1/04, A61K 9/0053, A61K 9/2013, A61K 9/2077, A61K 31/195, A61K 45/06, A61K 47/18, A61K2300/00Filed as Novo Nordisk A/S2026-03-16Per Sauerberg | pending |
| Procoagulant AntibodiesA61P 7/04, C07K 16/36, A61K2039/505, C07K2317/21, C07K2317/24, C07K2317/31, C07K2317/34, C07K2317/35, C07K2317/55, C07K2317/565, C07K2317/75, C07K2317/92Filed as Novo Nordisk A/S2026-02-10Karina Thorn | pending |
| INHIBITORS OF IL11RA BASED SIGNALLING COMPRISING TWO DIFFERENT IL11RA BINDING POLYPEPTIDESC07K 14/31, C07K 14/7155, A61P 7/10, A61P 9/00, A61P 9/06, A61P 9/04, A61K 38/00, C07K 14/395, C07K 14/5431, C07K2319/00, C07K2319/30, C07K2319/31, C07K2319/705Filed as Novo Nordisk A/S2026-02-06Jendrik Schoeppe | pending |
| SEMAGLUTIDE IN MEDICAL THERAPYA61P 3/04, A61K 38/26, A61K 9/0019, A61K 9/08, A61K 9/10, A61K 47/10Filed as Novo Nordisk A/S2026-01-29Maria Kabisch | pending |
| COMPOSITIONS AND METHODS FOR PROGRAMMED DEATH LIGAND RECEPTOR (PD-L1) EXPRESSIONC12N 15/1138, A61P 35/00, A61K 31/7088, A61K 31/712, A61K2039/505, C07K 16/2818, C12N2310/11, C12N2310/14, C12N2310/315, C12N2310/317, C12N2310/321, C12N2310/322, C12N2310/344, C12N2310/345, C12N2310/346, C12N2310/3515, C12N2310/531, C12N2320/31, C12N2310/3533, C12N2310/3521, C12N2310/3525Filed as NOVO NORDISK A/S2026-01-27Shanthi Ganesh | pending |
| METHODS OF ADMINISTERING FVIII MIMETIC BISPECIFIC ANTIBODIES ONCE EVERY SECOND MONTHC07K 16/36, A61P 7/04, A61K2039/505, A61K2039/545, C07K2317/31, C07K2317/565Filed as Novo Nordisk Healthcare AG2025-12-18Mads Kreilgaard | pending |
| PHARMACEUTICAL FORMULATIONSA61K 9/0019, A61K 9/08, A61K 38/26, A61P 25/28, A61P 1/16, A61P 9/00, A61P 3/04, A61P 3/10, A61K 31/4172, A61K 36/26, A61K 38/1703, A61K 47/02, A61K 47/10, A61K 47/12, A61K 47/183, A61K 47/22, A61K 47/24, A61K 47/26, A61M 5/19Filed as Novo Nordisk A/S2025-12-17Tommy Sander | 12741014 |
| SEMAGLUTIDE IN MEDICAL THERAPYA61P 3/10, A61K 38/26, A61P 9/00, A61P 9/04, A61K 47/24Filed as Novo Nordisk A/S2025-12-17Mikhail Kosiborod | pending |
| ALK7 BINDING PROTEINSC07K 16/2863, A61P 9/00, A61P 3/04, A61P 3/10, A61K 39/39591, A61K2039/505, C07K2317/24, C07K2317/34, C07K2317/55, C07K2317/92, C07K2317/94Filed as Novo Nordisk A/S2025-12-17Hans Dennis Aasberg | pending |
| PHARMACEUTICAL FORMULATIONSA61K 9/0019, A61K 9/08, A61K 38/26, A61P 25/28, A61P 1/16, A61P 9/00, A61P 3/04, A61P 3/10, A61K 31/4172, A61K 36/26, A61K 38/1703, A61K 47/02, A61K 47/10, A61K 47/12, A61K 47/183, A61K 47/22, A61K 47/24, A61K 47/26, A61M 5/19Filed as Novo Nordisk A/S2025-12-15Tommy Sander | 12741013 |
| PHARMACEUTICAL FORMULATIONS OF AN AMYLIN RECEPTOR AGONIST AND A GLP-1 RECEPTOR AGONIST COMPRISING A CYCLODEXTRINA61K 9/08, A61K 38/26, A61K 47/10, A61K 47/12, A61K 47/183, A61K 47/22, A61K 47/26, A61K 47/40Filed as Novo Nordisk A/S2025-12-12Benjamin Troest Kjeldsen | pending |
| CO-AGONISTS OF THE GLP-1 AND AMYLIN RECEPTORSC07K 14/575, C07K 14/605, A61K 47/542, A61P 25/28, A61P 1/16, A61P 3/00, A61P 9/00, A61P 3/04, A61P 3/10, A61K 38/00, A61K 38/22, A61K 38/26, C07K2319/00, C07K2319/75Filed as Novo Nordisk A/S2025-12-04Thomas Kruse | pending |
| Oral Dosing of GLP-1 CompoundsA61K 9/2013, A61K 38/26, A61P 43/00, A61P 3/04, A61P 3/10, A61K 9/0053, A61K 9/20, A61K 9/2054, A61K 31/166Filed as Novo Nordisk A/S2025-12-03Flemming S. Nielsen | pending |
| TRI-AGONISTS OF THE GLP-1, GIP, AND AMYLIN RECEPTORS AND USES THEREOFA61K 47/542, A61K 47/64, A61K 47/65, A61P 3/04, C07K 14/605Filed as Novo Nordisk A/S2025-12-01Thomas Kruse | pending |
| Treatment of diuretic resistant heart failure patients having at least one copy of the TMPRSS6 rs855791 alleleA61P 7/10, A61K 39/3955, C07K 16/24, C07K 16/248, A61P 13/12, A61K 45/06, A61K2039/505, A61K2300/00, C07K2317/76Filed as Novo Nordisk A/S2025-11-24Jeffrey Testani | pending |
| AMINOACYL-TRNA SYNTHETASES AND USES HEREOFC12N 9/93, C07K 14/605, C12P 21/02, C12Y 601/01, C12Y 601/01007Filed as Novo Nordisk A/S2025-11-24Hongtao Guan | pending |
| THERAPEUTIC METHODS AND USES FOR ANTIBODIES TO HUMAN MASP-3Filed as NOVO NORDISK HEALTH CARE AG2025-11-19WILLIAM JASON CUMMINGS | pending |
| GALNAC-CONJUGATED RNAI OLIGONUCLEOTIDESC12N 15/113, A61P 1/16, C12N2310/14, C12N2310/312, C12N2310/315, C12N2310/321, C12N2310/322, C12N2310/351Filed as NOVO NORDISK A/S2025-11-07Martin Lee Koser | pending |
| SEMAGLUTIDE IN THE TREATMENT OF PERIPHERAL ARTERIAL DISEASEA61P 3/10, A61K 38/26, A61P 9/10Filed as Novo Nordisk A/S2025-11-04Andrei-Mircea Catarig | pending |
| SHIELDED NEEDLE UNIT WITH ACTUATABLE MOUNTING FEATUREA61M 5/002, A61M 5/3202, A61M 5/3213, A61M 5/3243, A61M 5/3245, A61M 5/326, A61M 5/3276, A61M 5/3293, A61M 5/348, A61M 5/50, A61M2005/208, A61M2005/3247, A61M2005/3253, A61M2005/3254, A61M2005/3267, A61M2205/273Filed as Novo Nordisk A/S2025-10-31Nicolai Michael Villadsen | pending |
| LONG-ACTING GROWTH HORMONE RECEPTOR ANTAGONIST AND USE THEREOFC07K 14/61, A61P 5/00, A61K 38/00, C07K2319/70Filed as Novo Nordisk A/S2025-10-31Carsten Behrens | pending |
| DRUG DELIVERY ASSEMBLY WITH DOUBLE-DOSE PREVENTIONA61M 5/34, A61M 5/2033, A61M 5/2422, A61M2005/3247Filed as Novo Nordisk A/S2025-10-31Nicolai Michael Villadsen | pending |
| Bicyclic Compounds for Ketohexokinase InhibitionC07D 487/04, A61K 31/198, A61K 31/4184, A61K 31/4188, A61K 31/426, A61K 31/437, A61K 31/4545, A61K 31/4985, A61K 31/499, A61K 31/5025, A61K 31/551, A61K 38/26Filed as Novo Nordisk US Holdings, Inc.2025-10-27Gavin Whitlock | pending |
| SHIELDED NEEDLE UNIT WITH ROTATING NEEDLEA61M 5/002, A61M 5/3204, A61M 5/3202, A61M 5/3213, A61M 5/3243, A61M 5/3276, A61M 5/3293, A61M 5/348, A61M 5/50, A61M2005/208, A61M2005/3247, A61M2005/3253, A61M2005/3254, A61M2005/3267, A61M2205/273Filed as Novo Nordisk A/S2025-10-17Nicolai Michael Villadsen | pending |
| SHIELDED NEEDLE UNIT WITH AXIAL MOUNTING FEATUREA61M 5/346, A61M 5/2429, A61M 5/3271Filed as Novo Nordisk A/S2025-10-17Nicolai Michael Villadsen | pending |
| GLP-1 DERIVATIVES AND USES THEREOFC07K 14/605, A61P 3/04, A61K 38/00Filed as Novo Nordisk A/S2025-10-16Lars Linderoth | pending |
| SHIELDED NEEDLE UNIT WITH ACTUATABLE CONTAINER COUPLINGA61M 5/20, A61M 5/3202, A61M 5/002, A61M 5/3213, A61M 5/3221, A61M 5/3245, A61M 5/326, A61M 5/3276, A61M 5/3293, A61M 5/348, A61M2005/2013, A61M2005/3206, A61M2005/3247, A61M2005/3253, A61M2005/3254, A61M2005/3267, A61M2202/0007Filed as Novo Nordisk A/S2025-10-13Nicolai Michael Villadsen | pending |
| SHIELDED NEEDLE UNIT WITH ACTUATABLE RELEASE FEATUREA61M 5/3202, A61M 5/3213, A61M 5/3293, A61M 5/348, A61M 5/50, A61M2005/2474, A61M2005/3247, A61M2005/3253, A61M2005/3267Filed as Novo Nordisk A/S2025-10-13Nicolai Michael Villadsen | pending |
| GLUCOSE SENSITIVE INSULIN DERIVATIVESA61K 47/545, C07K 14/62, A61K 47/542, A61P 3/10, A61K 38/00, A61K 38/28Filed as Novo Nordisk A/S2025-10-10Thomas Hoeg-Jensen | pending |
| ANTAGONISTS OF HUMAN FGF23C07K 14/31, C07K 14/50, A61P 43/00, A61P 19/08, A61K 38/00, A61K 38/164, C07K 14/4702, C07K2319/01Filed as Novo Nordisk A/S2025-10-10Christian Wenzel Tornoee | pending |
| TRI-AGONISTS OF THE GLP-1, GIP, AND AMYLIN RECEPTORSA61K 47/542, A61K 38/08, C07K 14/575, C07K 14/72, A61K 47/65, A61K 47/55, A61K 47/64, A61P 3/04, A61K 38/00, A61K 38/26, C07K 7/06, C07K 7/08, C07K 14/001, C07K 14/585, C07K 14/605Filed as Novo Nordisk A/S2025-09-15Thomas Kruse | pending |
| NOVEL ANTI-ANGPTL3 ANTIBODIES SUITABLE FOR HIGH CONCENTRATION COMPOSITIONS AND SUBCUTANEOUS ADMINISTRATIONC07K 16/22, A61P 9/10, A61P 3/06, A61P 3/10, A61K 39/39591, A61K2039/505, A61K2039/54, A61K2039/545, C07K2317/35, C07K2317/524, C07K2317/526, C07K2317/565, C07K2317/76, C07K2317/92, C07K2317/94Filed as Novo Nordisk A/S2025-09-11Anette Henriksen | pending |
| DRUG DELIVERY DEVICE WITH PLUNGER ROD HAVING NONUNIFORM STOPPER INTERFACEA61M 5/2033, A61M 5/31513, A61M 5/31596, A61M 5/31598, A61M 5/31, A61M 5/31515, A61M 5/3202, A61M 5/3213, A61M2005/202, A61M2005/31521Filed as Novo Nordisk A/S2025-09-09Klaus Bendix | pending |
| SEMAGLUTIDE IN MEDICAL THERAPY INCLUDING WEIGHT MANAGEMENTA61K 38/26, A61P 9/10, A61P 1/16, A61P 3/04, A61P 3/10, A61P 13/12, A61K 9/0019, A61K 38/22, A61K2300/00Filed as Novo Nordisk A/S2025-08-28Rune Viig Overgaard | pending |
| SEMAGLUTIDE FOR USE IN MEDICINEA61K 38/26, A61P 1/16, A61K 9/0019, A61K 9/0021, A61K 47/02, A61K 47/10Filed as Novo Nordisk A/S2025-08-27Morten Hansen | pending |
| COMPOSITIONS AND METHODS FOR INHIBITING XDH EXPRESSIONC12N 15/1137, A61K 31/712, C12N2310/14, C12N2310/315, C12N2310/321, C12N2310/322, C12N2310/351, C12Y 117/01004, C12N2310/531, C12N2310/3521, C12N2310/3533, A61K2300/00Filed as NOVO NORDISK A/S2025-08-21Allison Cherry Ostriker | 12709752 |
| HOMING ENDONUCLEASE VARIANTSC12N 9/22, C12N 15/907, C07K2319/80, C12N 15/62Filed as Novo Nordisk A/S2025-08-19Jordan JARJOUR | pending |
| SOLID COMPOSITIONS COMPRISING A GLP-1 AGONIST AND A SALT OF N-(8-(2-HYDROXYBENZOYL)AMINO)CAPRYLIC ACIDA61K 9/2013, A61K 38/26, A61P 3/04, A61P 3/10, A61K 45/06, A61K 47/12, A61K 47/14, A61K 47/18, C07K 14/605Filed as Novo Nordisk A/S2025-07-23Betty Lomstein Pedersen | pending |
| CHEMICAL MODIFICATIONS OF SMALL INTERFERING RNA WITH MINIMAL FLUORINE CONTENTC12N 15/113, C12N 15/1137, A61K 31/712, C12N2310/14, C12N2310/321, C12N2310/322, C12N2310/344, C12N2310/351, C12N2310/3515, C12N2310/3533, C12N2310/531, C12N2310/533Filed as NOVO NORDISK A/S2025-07-10Weimin WANG | pending |
| ANTI IL-6 DOMAIN ANTIBODIES WITH FATTY ACID SUBSTITUENTSC07K 16/248, C07K 16/2866, A61P 9/10, A61P 9/00, A61P 29/00, A61K 9/0053, A61K 9/2013, A61K 31/20, A61K 31/455, A61K 31/609, A61K 39/3955, A61K 39/39591, A61K2039/505, A61K2039/54, A61K2039/542, A61K2039/545, A61K2300/00, C07K 14/5412, C07K2317/22, C07K2317/24, C07K2317/34, C07K2317/56, C07K2317/565, C07K2317/569, C07K2317/76, C07K2317/92, C07K2317/94, C07K2319/31Filed as Novo Nordisk A/S2025-07-10Thomas Egebjerg | pending |
| METHOD AND EQUIPMENT FOR FRACTIONATION OF GRANULES FOR USE IN PHARMACEUTICAL COMPOSITIONSA61K 9/1682, A61K 31/609, B07B 1/38, B07B 13/16, B07B2230/04, A61J 3/00, A61K 9/141, A61K 9/146, A61K 9/16Filed as Novo Nordisk A/S2025-06-27Thomas Kvistgaard Vilhelmsen | pending |
| Amylin Receptor AgonistsA61K 38/00, C07K 14/4705, C07K 14/575, A61P 3/04, A61P 3/10, C07K 14/605, C07K 14/72Filed as Novo Nordisk A/S2025-06-13Cecilie Mia Joergensen | pending |
| RECOMBINANT PROTEASE FOR CELL DETACHMENTC12N 5/0018, C12N 9/6405, C07K 14/43504, C12N 9/48, C12N 9/6408, C12N2501/734Filed as Novo Nordisk Pharmatech A/S2025-06-13Tine HOFF | pending |
| MICROBIAL PROTEASES FOR CELL DETACHMENTC12N 5/0018, C12N 9/52, C12N 9/58, C12N 15/75, C12R2001/01, C12R2001/645, C12N 5/0607, C12N 5/0696, C12N 15/80, C12N2501/734, C12N2509/00, C12Y 304/21Filed as Novo Nordisk Pharmatech A/S2025-06-13Tine HOFF | pending |
| RECOMBINANT PROTEASE FOR CELL DETACHMENTC12N 9/6427, C12N 9/52, C12N 9/6489, C12Y 304/21001, C12Y 304/21004, C12Y 304/24003, C12Y 304/24024Filed as Novo Nordisk Pharmatech A/S2025-06-13Tine HOFF | pending |
| NK CELL ACTIVATING RECEPTOR LIGAND KNOCKOUTS FOR USE IN CELL THERAPYC12N 5/0676, A61K 35/39, A61K 35/545, C07K 14/70539, C07K2319/00, C12N 5/0606, C12N 5/0607, C12N 5/0613, C12N 5/0696, C12N 15/62, C12N2510/00Filed as Novo Nordisk A/S2025-06-06Gunther Roland Galler | pending |
| METHODS AND COMPOSITIONS FOR INHIBITING EXPRESSION OF LDHAC12N 15/1137, A61P 3/00, A61P 13/00, A61P 13/04, A61K 9/0019, A61K 31/7088, C12N2310/11, C12N2310/14, C12N2310/315, C12N2310/321, C12N2310/322, C12N2310/344, C12N2310/351, C12N2310/3515, C12N2310/3521, C12N2310/3533, C12Y 101/01027Filed as Novo Nordisk Healthcare AG2025-05-23Bob D. Brown | pending |
| STAT3 TARGETING OLIGONUCLEOTIDES AND USES THEREOFC12N 15/113, A61P 35/00, A61K 31/7088, A61K 45/06, C07K 16/2818, C07K 16/2827, C12N2310/11, C12N2310/14, C12N2310/312, C12N2310/315, C12N2310/3515, C12N2310/531, C12N2320/31Filed as NOVO NORDISK A/S2025-05-16Marc Abrams | 12674161 |
Filings are matched to the company by applicant name, so a subsidiary filing under its own name is only here if that name resolves to this company. The applicant is printed as filed, which makes a wrong match visible. A patent is not a product: most applications are never granted, and most grants are never built.
More on NVO
Company overviewEverything on NVO in one place, with the price.SEC filingsWhat NVO's 8-Ks say happened: results, departures, auditor changes.Who owns itEvery manager reporting a position in NVO.Funds holding itWhich funds and ETFs hold NVO, and how big a bet.LobbyingWhat NVO spends lobbying Congress, and on what.Who lobbies for itThe lobbyists on NVO's account, and who they worked for.